

REMARKS

The specification has been amended to provide a cross-reference to the previously filed International Application. The claims have also been amended to delete improper multiple dependencies and to place the application into better form for examination. Entry of the present amendment and favorable action on the above-identified application are earnestly solicited.

Attached hereto is a marked-up copy of the changes made to the application by this Amendment.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By *Leonard R. Svensson* #30,623
Leonard R. Svensson, #30,330

LRS/cgc
3631-0109P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachment: Version With Markings Showing Changes Made

(Rev. 11-22-01)

VERSION WITH MARKINGS SHOWING CHANGES MADE

The specification has been amended to provide cross-referencing to the International Application.

The claims have been amended as follows:

3. (Amended) The method according to claim 1 [or 2], wherein said at least one CTL epitope when presented is associated with an MHC Class I molecule on the surface of the APC and/or wherein said at least one first foreign T_H epitope when presented is associated with an MHC Class II molecule on the surface of the APC.

4. (Amended) The method according to [any one of the preceding claims]claim 1, wherein the APC is a dendritic cell or a macrophage.

5. (Amended) The method according to [any one of the preceding claims]claim 1, wherein the polypeptide antigen is selected from a tumour-associated polypeptide antigen, a self-protein, a viral polypeptide antigen, and a polypeptide antigen derived from an intracellular parasite or bacterium.

6. (Amended) The method according to [any one of the preceding claims]claim 1, wherein presentation by the APC of the CTL epitope and the first foreign T_H epitope is effected by presenting the animal's immune system with at least one first

analogue of the polypeptide antigen, said first analogue comprising a variation of the amino acid sequence of the polypeptide antigen, said variation containing at least the CTL epitope and the first foreign T_H epitope.

9. (Amended) The method according to [any one of claims 6-8]claim 6, wherein substantially all known CTL epitopes of the cell-associated polypeptide antigen are present in the analogue and/or wherein substantially all predicted CTL epitopes of the cell-associated polypeptide antigen are present in the at least first analogue.

10. (Amended) The method according to [any one of claims 6-9]claim 6, wherein the at least one first analogue further comprises a part consisting of a modification of the structure of the cell-associated polypeptide antigen, said modification having as a result that immunization of the animal with the first analogue induces production of antibodies in the animal against the cell-associated polypeptide antigen.

11. (Amended) The method according to [any one of the preceding claims]claim 1, which comprises effecting presentation to the animal's immune system of an immunogenically effective amount of at least one second analogue of the polypeptide antigen, said second analogue containing a modification of the structure of the polypeptide antigen, said modification having as a result that immunization of the animal with the second analogue

induces production of antibodies against the cell-associated polypeptide antigen.

13. (Amended) The method according to [any of claims 6-12]claim 6, wherein the first and/or second analogue(s) comprise(s) a substantial fraction of the cell-associated polypeptide antigen's B-cell epitopes.

14. (Amended) The method according to [any of claims 6-13]claim 6, wherein the variation and/or modification involves amino acid substitution and/or deletion and/or insertion and/or addition.

15. (Amended) The method according to [any of claims 6-14]claim 6, wherein the variation and/or modification comprises that

- at least one first moiety is included in the first and/or second analogue(s), said first moiety effecting targeting of the analogue to an antigen presenting cell (APC), and/or
- at least one second moiety is included in the first and/or second analogue(s), said second moiety stimulating the immune system, and/or
- at least one third moiety is included in the first and/or second analogue(s), said third moiety optimizing presentation of the analogue to the immune system.

16. (Amended) The method according to [any of claims 6-15]claim 6, wherein the variation and/or modification includes duplication of at least one B-cell epitope or of at least one CTL epitope of the cell-associated polypeptide antigen.

17. (Amended) The method according to [any of claims 6-16]claim 6, wherein the variation and/or modification includes introduction of a hapten.

18. (Amended) The method according to [any one of the preceding claims]claim 1, wherein the first and/or second foreign T_H epitope(s) is/are immunodominant.

19. (Amended) The method according to [any one of the preceding claims]claim 1, wherein the first and/or second foreign T_H epitope(s) is/are promiscuous.

20. (Amended) The method according to [any one of claims 12-19]claim 12, wherein the first and/or second foreign T_H epitope(s) is/are selected from a natural T_H epitope and an artificial MHC-II binding peptide sequence.

22. (Amended) The method according to [any one of claims 12-21]claim 12, wherein the first and/or second T_H epitopes and/or first and/or second and/or third moieties are present in the form of

- side groups attached covalently or non-covalently to suitable chemical groups in the amino acid sequence of the cell-associated polypeptide antigen or a subsequence thereof, and/or
- fusion partners to the amino acid sequence derived from the cell-associated polypeptide antigen.

24. (Amended) The method according to [any one of claims 15-23]claim 15, wherein the second moiety is a cytokine selected from interferon γ (IFN- γ), Flt3L, interleukin 1 (IL-1), interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 6 (IL-6), interleukin 12 (IL-12), interleukin 13 (IL-13), interleukin 15 (IL-15), and granulocyte-macrophage colony stimulating factor (GM-CSF), or an effective part thereof; a heat-shock protein selected from HSP70, HSP90, HSC70, GRP94, and calreticulin (CRT), or an effective part thereof; or a hormone.

25. (Amended) The method according to [any one of claims 15-24]claim 15, wherein the third moiety is a lipid such as a palmitoyl group, a myristyl group, a farnesyl group, a geranyl-geranyl group, a GPI-anchor, and an N-acyl diglyceride group.

26. (Amended) The method according to [any one of claims 6-25]claim 6, wherein the first and/or second analogue(s) has/have substantially the overall tertiary structure of the cell-associated polypeptide antigen.

27. (Amended) The method according to [any one of claims 6-26]claim 6, wherein presentation by the APC is effected by administering, to the animal, an immunogenically effective amount of the at least one first analogue.

29. (Amended) The method according to claim 27 [or 28], wherein said at least one first and/or second analogue(s) is/are formulated together with a pharmaceutically and immunologically acceptable carrier and/or vehicle and, optionally an adjuvant.

33. (Amended) The method according to [any one of claims 27-32]claim 27, which includes administration via a route selected from the oral route and the parenteral route such as the intradermal, the subdermal, the intracutaneous, the subcutaneous; the peritoneal, the buccal, the sublingual, the epidural, the spinal, the anal, and the intracranial routes.

34. (Amended) The method according to [any of claim 27-33]claim 27, which includes at least one administration a year, such as at least 2, 3, 4, 5, 6, and 12 administrations a year.

35. (Amended) The method according to [any one of claims 1-5]claim 1, wherein presentation is effected by administering, to the animal, a non-pathogenic microorganism or virus which is carrying a nucleic acid fragment encoding and expressing the at least one CTL epitope and the at least one T_H epitope.

36. (Amended) The method according to [any one of claims 6-14]claim 6, wherein presentation is effected by administering, to the animal, a non-pathogenic microorganism or virus which is carrying at least one nucleic acid fragment which encodes and expresses the at least first analogue.

37. (Amended) The method according to [any one of claims 15-26]claim 15, wherein the T_H epitope and/or the first and/or second and/or third moieties are present in the form of fusion partners to the amino acid sequence derived from the cell-associated polypeptide antigen, and wherein presentation is effected by administering, to the animal, a non-pathogenic microorganism or virus which is carrying at least one nucleic acid fragment encoding and expressing the first and/or second analogue.

38. (Amended) The method according to [any one of claims 11-14 or 36]claim 11, wherein presentation is effected by administering, to the animal, a non-pathogenic microorganism or virus which is carrying at least one nucleic acid fragment which encodes and expresses the at least second analogue.

40. (Amended) The method according to [any one of claims 1-5]claim 1, wherein presentation is effected by in vivo introducing, into the APC, at least one nucleic acid fragment which encodes and expresses the at least one CTL epitope and/or the at least one B-cell epitope, and the at least one first foreign T_H epitope.

41. (Amended) The method according to [any one of claims 6-14]claim 6, wherein presentation is effected by in vivo introducing, into the APC, at least one nucleic acid fragment encoding and expressing the first analogue.

42. (Amended) The method according to [any one of claims 15-26]claim 15, wherein the T_H epitope and/or the first and/or second and/or third moieties are present in the form of fusion partners to the amino acid sequence derived from the cell-associated polypeptide antigen, and wherein presentation is effected by in vivo introducing, into the APC, at least one nucleic acid fragment encoding and expressing the first and/or second analogue.

43. (Amended) The method according to [any one of claims 11-14 and 41]claim 11, which further comprises in vivo introduction, into the APC, of at least one nucleic acid fragment encoding and expressing the second analogue.

44. (Amended) The method according to [any one of claims 1-5]claim 1, wherein presentation is effected by in vivo co-introducing, into the APC, at least two nucleic acid fragments, wherein one encodes and expresses the at least one CTL epitope and wherein another encodes and expresses the at least one first foreign T_H epitope, and wherein the first foreign T_H epitope is as defined in [any one of claims 1, 2 and 21-24]claim 1.

45. (Amended) The method according to [any one of claims 40-44]claim 40, wherein the nucleic acid fragment(s) introduced is/are selected from naked DNA, DNA formulated with charged or uncharged lipids, DNA formulated in liposomes, DNA included in a viral vector, DNA formulated with a transfection-facilitating protein or polypeptide, DNA formulated with a targeting protein or polypeptide, DNA formulated with a targeting carbohydrate, DNA formulated with Calcium precipitating agents, DNA coupled to an inert carrier molecule, and DNA formulated with an adjuvant.

46. (Amended) The method according to claim 45, wherein the adjuvant is selected from the group consisting of the adjuvants defined in [any one of claims 30-32]claim 30.

47. (Amended) The method according to [any one of claims 40-46]claim 40, wherein the mode of administration is as defined in claim 33 [or 34].

51. (Amended) A method for the preparation of cell producing an analogue of a cell-associated polypeptide antigen, the method comprising introducing, into a vector, a nucleic acid sequence encoding an analogue which has been selected according to the method of [any one of claims 48-50]claim 48 and transforming a suitable host cell with the vector.

54. (Amended) The method according to [any one of the preceding claims]claim 1, wherein the weak cell-associated antigen is selected from the group consisting of 5 alpha reductase, α -fetoprotein, AM-1, APC, APRIL, BAGE, β -catenin, Bcl2, bcr-abl (b3a2), CA-125, CASP-8 / FLICE, Cathepsins, CD19, CD20, CD21, CD23, CD22, CD33, CD35, CD44, CD45, CD46, CD5, CD52, CD55 (791Tgp72), CD59, CDC27, CDK4, CEA, c-myc, Cox-2, DCC, DcR3, E6 / E7, EGFR, EMBP, Ena78, farsyl transferase, FGF8a or FGF8b, FLK-1/KDR, Folic Acid Receptor, G250, GAGE-Family, gastrin 17, Gastrin-releasing hormone (Bombesin), GD2 / GD3 / GM2, GnRH, GnTV, GP1, gp100 / Pmel 17, gp-100-in4, gp15, gp75 / TRP-1, hCG, Heparanase, Her2 / neu, HMTV, Hsp70, hTERT (telomerase), IGFR1, IL-13R, iNOS, Ki 67, KIAA0205, K-ras, H-ras, N-ras, KSA (CO17-1A), LDLR-FUT, MAGE Family (MAGE-1, MAGE-2, MAGE-3, etc), Mammaglobin, MAP17, Melan-A / MART-1, mesothelin, MIC A/B, MT-MMP's, Mox1, Mucin such as MUC-1, MUC-2, MUC-3, and MUC-4 being abberantly glycosylated, MUM-1, NY-ESO-1, Osteonectin, p15, P170 / MDR1, p53, p97 / melanotransferrin, PAI-1, PDGF, Plasminogen (uPA), PRAME, Probasin, Progenipoietin, PSA, PSM, RAGE-1, Rb,

RCAS1, SART-1, SSX gene family, STAT3, STn (mucin assoc.), TAG-72, TGF- α , TGF- β , Thymosin β 15, TNF- α , TPA, TPI, TRP-2, Tyrosinase, VEGF, ZAG, p16INK4, and Glutathione S-transferase.

57. (Amended) The method according to claim 55 [or 56] used in the treatment or amelioration of prostate cancer.

60. (Amended) The method according to claim 58 [or 59] used in the treatment or amelioration of cancer such as prostate cancer and breast cancer.

63. (Amended) The method according to claim 61 [or 62] used in the treatment or amelioration of breast cancer.

64. (Amended) An analogue of human PSM which is immunogenic in humans, said analogue comprising a substantial part of all known and predicted CTL and B-cell epitopes of PSM and including at least one foreign T_H epitope as defined in [any one of claims 18-21]claim 18.

67. (Amended) An analogue of human Her2 which is immunogenic in humans, said analogue comprising a substantial part of all known and predicted CTL and B-cell epitopes of Her2 and including at least one foreign T_H epitope as defined in [any one of claims 18-21]claim 18.

70. (Amended) An analogue of human/murine FGF8b which is immunogenic in humans, said analogue comprising a substantial part of all known and predicted CTL and B-cell epitopes of FGF8b and including at least one foreign T_H epitope as defined in [any one of claims 18-21]claim 18.

73. (Amended) An immunogenic composition which comprises, as an effective immunogenic agent the analogue according to [any one of claims 64-72]claim 64 in admixture with a pharmaceutically and immunologically acceptable carrier or vehicle, and optionally an adjuvant.

74. (Amended) A nucleic acid fragment which encodes an analogue according to [any one of claims 64-72]claim 64.

77. (Amended) The vector according to claim 75 [or 76] which is selected from the group consisting of a plasmid, a phage, a cosmid, a mini-chromosome, and a virus.

78. (Amended) The vector according to [any one of claims 75-77]claim 75, comprising, in the 5'3' direction and in operable linkage, a promoter for driving expression of the nucleic acid fragment according to claim 74, optionally a nucleic acid sequence encoding a leader peptide enabling secretion of or integration into the membrane of the polypeptide fragment, the nucleic acid fragment according to claim 74, and optionally a nucleic acid sequence encoding a terminator.

79. (Amended) The vector according to [any one of claims 75-78]claim 75 which, when introduced into a host cell, is integrated in the host cell genome or is not capable of being integrated in the host cell genome.

80. (Amended) A transformed cell carrying the vector of [any one of claims 75-79]claim 75.

81. (Amended) A composition for inducing production of antibodies against PSM, Her2 or FGF8b, the composition comprising

3) a nucleic acid fragment according to claim 74 or a vector according to [any one of claims 75-79]claim 75, and

4) a pharmaceutically and immunologically acceptable diluent and/or vehicle and/or adjuvant.

82. (Amended) A stable cell line which carries the vector according to [any one of claims 75-79]claim 75 and which expresses the nucleic acid fragment according to claim 74, and which optionally secretes or carries the analogue according to [any one of claims 64-72]claim 64 on its surface.

83. (Amended) A method for the preparation of the cell according to claim 80, the method comprising transforming a host cell with the nucleic acid fragment according to claim 74 or with the vector according to [any one of claims 75-79]claim 75.

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: L. STEINAA et al. Conf.: 5928
Appl. No.: 09/806,703 Group: UNKNOWN
Filed: April 4, 2001 Examiner: UNKNOWN
For: NOVEL METHODS FOR THERAPEUTIC VACCINATION

PETITION TO INCLUDE FORMAL DRAWINGS

Assistant Commissioner for Patents
Washington, DC 20231

November 13, 2001

Sir:

The present application is a National Stage application of International Application PCT/DK99/00525. Applicants' Representative has discovered that no drawings were filed with the copy of the application sent by the Applicant to the USPTO upon entry of this application into National Stage prosecution.

Accordingly, Applicants provide here formal drawings and request that they be entered into the application for use in publication of the patent upon issuance.

The specification of the International Application may serve as the application for examination in the National Stage if transmitted to a Designated Office by the International Bureau. (PCT Article 11(3), PCT Article 20, 35 U.S.C. §371 (c)). Attached is a copy of the Transmittal for the entry of the application into the National Stage (Form PTO-1390), showing the transmitted copy is to be used as the record copy for examination.

The attached drawings should not be considered new matter, as they are present in the International Application PCT/DK99/00525. The attached drawings were in fact printed from the electronic copy of International Application PCT/DK99/00525 maintained on esp@cenet at <http://12.espacenet.com/dips/bnsviewer?CY=wo&LG=en&DB=EPD&PN=0020027&ID=WO++-0020027A2+I+>.

The Fee of \$130.00 for consideration of this petition is attached hereto.

11/14/2001 SHAJARRD 00000032 09806703

01 FC:122

130.00 0P

Appl. No. 02-16,703

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. §§1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By *Leonard R. Svensson* 36633
Leonard R. Svensson, #30,330

LRS/SWG/CAV
3631-0109P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000